Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Chantharasamee

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

BMC Cancer

English

Related publications

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

English

Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced Non-Small Cell Lung Cancer Patients: A Single Center Retrospective Analysis

Lung Cancer: Targets and Therapy

Oncology

2019

English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology

English

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

English

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology

English

EGFR Mutation Status in Tunisian Non-Small-Cell Lung Cancer Patients Evaluated by Mutation-Specific Immunohistochemistry

BMC Pulmonary Medicine

Pulmonary

Respiratory Medicine

2018

English

Association of Exon 19 and 21 EGFR Mutation Patterns With Treatment Outcome After First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Chantharasamee

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

Related publications

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced Non-Small Cell Lung Cancer Patients: A Single Center Retrospective Analysis

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

EGFR Mutation Status in Tunisian Non-Small-Cell Lung Cancer Patients Evaluated by Mutation-Specific Immunohistochemistry

Association of Exon 19 and 21 EGFR Mutation Patterns With Treatment Outcome After First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer